Eosinophilic Esophagitis: Novel Therapeutic Developments and Impact on Treatment Paradigms

Overview

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Activity Description

Eosinophilic esophagitis (EoE) is a chronic, type-2 helper (Th2)-mediated inflammatory disorder that affects both children and adults. It is characterized by symptoms of esophageal dysfunction and esophageal inflammation with intraepithelial eosinophils. Once considered rare, EoE is a relatively new disease that is now commonplace. When left unmanaged, EoE can impact a patient’s ability to eat properly, leading to food impaction and increased medical expenses. Real-world data indicate that many patients with EoE switch therapy frequently, demonstrating an unmet need for adequate control of disease-related symptoms. Many gastroenterologists and other relevant health care providers lack an understanding of the pathogenesis, guideline-based diagnostic criteria, and newly approved and emerging treatment options for EoE. These knowledge deficits may therefore exacerbate delays in diagnoses and, consequently, appropriate management. In this educational program, expert clinicians review the pathogenesis and best practices for the accurate diagnosis of EoE. They also explore current treatment guidelines and the clinical data supporting the use of recently approved and emerging therapies for EoE. Interactive case discussions are included to challenge the audience’s ability to apply the learnings from the didactic presentations.

Target Audience

The intended audience for this activity is gastroenterologists and other health care professionals involved in the management of patients with EoE.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Identify the latest findings on the pathogenesis of EoE.
• Summarize the criteria for diagnosis of EoE and tools to detect the condition.
• Outline the clinical evidence for current, newly approved, and emerging therapies for EoE including the latest guideline recommendations.

Activity Chair

Evan S. Dellon, MD, MPH
Professor
Division of Gastroenterology and Hepatology
Department of Medicine
University of North Carolina School of Medicine
Chapel Hill, NC

Faculty

Claire Beveridge, MD
Associate Staff
Department of Gastroenterology, Hepatology & Nutrition
Cleveland Clinic
Assistant Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, OH

Mirna Chehade, MD, MPH
Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, NY

Ikuo Hirano, MD, FACG
Professor of Medicine
Division of Gastroenterology and Hepatology
Northwestern University Feinberg School of Medicine
Chicago, IL

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 30, 2022, to December 29, 2023.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relevant financial relationship(s)

Claire Beveridge, MD
Advisor: Lucid Diagnostics
Consultant: Lucid Diagnostics

Mirna Chehade, MD, MPH
Consultant: Adare/Ellodi, Allakos, AstraZeneca, Bristol Myers Squibb, Regeneron, Sanofi, Shire/Takeda
Independent Research Contractor: Adare/Ellodi, Allakos, AstraZeneca, Danone, Regeneron, Shire/Takeda

Evan S. Dellon, MD, MPH
Consultant: Abbott, AbbVie, Adare/Ellodi, Aimmune, ALK, Allakos, Amgen, Arena, AstraZeneca, Avir, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, EsoCap, GlaxoSmithKline, Gossamer Bio, Landos, Nexstone, Regeneron, Revolo, Sanofi, Shire/Takeda, Upstream Bio
Independent Research Contractor: Adare/Ellodi, Allakos, Arena, AstraZeneca, Celgene/Receptors/Bristol Myers Squibb, GlaxoSmithKline, Meritage, Regeneron, Revolo, Shire/Takeda

Ikuo Hirano, MD, FACG
Consultant: Allakos, Arena, AstraZeneca, Bristol Myers Squibb/Celgene, Ellodi/Adare, Sanofi/Regeneron, Takeda/Shire
Speaker Contracted by Ineligible Company: Sanofi/Regeneron

Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com